
Nduka M Amankulor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/582505/publications.pdf Version: 2024-02-01



Νοικά Μ. Δμανκιμορ

#	Article	IF	CITATIONS
1	In vivo efficacy of decitabine as a natural killer cell–mediated immunotherapy against isocitrate dehydrogenase mutant gliomas. Neurosurgical Focus, 2022, 52, E3.	2.3	2
2	A liquid fraction of extracellular matrix inhibits glioma cell viability <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2022, 13, 426-438.	1.8	0
3	A Novel 5-Aminolevulinic Acid-Enabled Surgical Loupe System—A Consecutive Brain Tumor Series of 11 Cases. Operative Neurosurgery, 2022, 22, 298-304.	0.8	7
4	The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling. Frontiers in Oncology, 2022, 12, 790976.	2.8	11
5	Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma using RNA Sequencing Expression Data. World Neurosurgery, 2022, , .	1.3	4
6	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nature Cancer, 2022, 3, 629-648.	13.2	16
7	Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology, 2021, 23, 783-794.	1.2	83
8	Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 2021, 41, 381-468.	2.4	8
9	Venous Thromboembolism Anticoagulation Prophylaxis Timing in Patients Undergoing Craniotomy for Tumor. Neurosurgery Open, 2021, 2, .	0.2	3
10	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	1.1	5
11	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Frontiers in Immunology, 2021, 12, 637146.	4.8	32
12	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. Journal of Clinical Investigation, 2021, 131, .	8.2	49
13	The Evolving Role of Induced Pluripotent Stem Cells and Cerebral Organoids in Treating and Modeling Neurosurgical Diseases. World Neurosurgery, 2021, 155, 171-179.	1.3	3
14	A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. Journal of Neuro-Oncology, 2021, 151, 103-112.	2.9	10
15	Headlight and loupe-based fluorescein detection system in brain tumor surgery; a firstin-human experience. Journal of Neurosurgical Sciences, 2021, , .	0.6	1
16	Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. Cancer Gene Therapy, 2020, 28, 971-983.	4.6	6
17	Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy, 2020, 12, 763-769.	2.0	7
18	Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. Molecular Cancer Therapeutics, 2020, 19, 1550-1561.	4.1	22

Nduka M Amankulor

#	Article	IF	CITATIONS
19	Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. Journal of Neurosurgery, 2020, 133, 1345-1354.	1.6	83
20	PATH-39. ASSOCIATIONS OF GENOMIC SUBGROUP WITH RECURRENCE IN LOW-GRADE MENINGIOMAS. Neuro-Oncology, 2020, 22, ii172-ii173.	1.2	1
21	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Research, 2019, 79, 4026-4041.	0.9	16
22	GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy - Oncolytics, 2019, 15, 214-222.	4.4	28
23	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight, 2019, 4, .	5.0	24
24	Isolation and characterization of exosomes from IDH mutant gliomas Journal of Clinical Oncology, 2019, 37, 152-152.	1.6	0
25	MNGI-09. MENINGIOMA WITH MULTIPLE DRIVERS: GENOMIC LANDSCAPE AND CLINICAL CORRELATIONS. Neuro-Oncology, 2019, 21, vi141-vi141.	1.2	0
26	The Utility of Early Postoperative Head Computed Tomography in Brain Tumor Surgery: A Retrospective Analysis of 755 Cases. World Neurosurgery, 2018, 111, e206-e212.	1.3	11
27	Long-Term Outcomes After Stereotactic Radiosurgery for Spine Metastases: Radiation Dose–Response for Late Toxicity. International Journal of Radiation Oncology Biology Physics, 2018, 101, 602-609.	0.8	26
28	2036 Extracellular matrix as a novel approach to glioma therapy. Journal of Clinical and Translational Science, 2018, 2, 11-12.	0.6	0
29	IMMU-18. TARGETING THE PD1 AND TIGIT CHECKPOINT PATHWAYS FOR ADULT AND PEDIATRIC GLIOMAS. Neuro-Oncology, 2018, 20, vi125-vi125.	1.2	Ο
30	TMIC-13. EFFICACY OF RETINOIC ACID IN REVERSING IMMUNE EVASION IN IDH MUTANT GLIOMAS. Neuro-Oncology, 2018, 20, vi258-vi258.	1.2	0
31	Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. Journal of Experimental and Clinical Cancer Research, 2018, 37, 255.	8.6	45
32	Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes and Development, 2017, 31, 774-786.	5.9	313
33	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood, 2017, 130, 1430-1440.	1.4	131
34	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biology, 2017, 18, 234.	8.8	448
35	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology, 2016, 18, 1402-1412.	1.2	126
36	Hyalinizing Clear Cell Carcinoma with Biopsy-Proven Spinal Metastasis: Case Report and Review of Literature. World Neurosurgery, 2016, 90, 699.e7-699.e10.	1.3	8

Nduka M Amankulor

#	Article	IF	CITATIONS
37	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology, 2016, 18, 379-387.	1.2	101
38	Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. Clinical Neurology and Neurosurgery, 2015, 130, 61-66.	1.4	27
39	Tumor Bed Radiosurgery Following Resection and Prior Stereotactic Radiosurgery for Locally Persistent Brain Metastasis. Frontiers in Oncology, 2015, 5, 84.	2.8	25
40	Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. Clinical Cancer Research, 2015, 21, 286-294.	7.0	92
41	Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Clioblastoma-targeted Oncolytic HSV. Molecular Therapy, 2015, 23, 99-107.	8.2	69
42	IB-03 * IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS. Neuro-Oncology, 2014, 16, v107-v107.	1.2	0
43	Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth. Cell Stem Cell, 2014, 14, 357-369.	11.1	411
44	The incidence and patterns of hardware failure after separation surgery in patients with spinal metastatic tumors. Spine Journal, 2014, 14, 1850-1859.	1.3	86
45	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521) Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	1.6	ο